Veradermics

Veradermics, a clinical-stage dermatology company, announced on October 16 the completion of an oversubscribed $150 million Series C financing round. The funding will support the advancement of its lead investigational candidate, VDPHL01—an extended-release oral formulation of minoxidil being studied for androgenic alopecia in both men and women. The company describes it as the first oral…